Havens Advisors adds St. Jude Medical (STJ) to its portfolio

St. Jude Medical (STJ) : Havens Advisors added new position in St. Jude Medical during the most recent quarter end. The investment management firm now holds 96,200 shares of St. Jude Medical which is valued at $7,739,290 , the company said in a statement filed on Jul 13, 2016 with the SEC.St. Jude Medical makes up approximately 6.74% of Havens Advisors’s portfolio.

Other Hedge Funds, Including , Somerset Trust Co sold out all of its stake in STJ during the most recent quarter. The investment firm sold 29,004 shares of STJ which is valued $2,333,372.Benjamin F. Edwards Company reduced its stake in STJ by selling 41 shares or 14.54% in the most recent quarter. The Hedge Fund company now holds 241 shares of STJ which is valued at $19,388.Boltwood Capital Management reduced its stake in STJ by selling 560 shares or 3.78% in the most recent quarter. The Hedge Fund company now holds 14,265 shares of STJ which is valued at $1,114,524. St. Jude Medical makes up approx 0.93% of Boltwood Capital Management’s portfolio.

St. Jude Medical opened for trading at $80.55 and hit $80.59 on the upside on Monday, eventually ending the session at $80.56, with a gain of 0.09% or 0.07 points. The heightened volatility saw the trading volume jump to 24,58,886 shares. Company has a market cap of $22,901 M.

On the company’s financial health, St. Jude Medical reported $0.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Apr 20, 2016. Analyst had a consensus of $0.88. The company had revenue of $1448.00 million for the quarter, compared to analysts expectations of $1437.78 million. The company’s revenue was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.93 EPS.

Many Wall Street Analysts have commented on St. Jude Medical. Company shares were Downgraded by Wedbush on Jul 15, 2016 to ” Neutral”, Firm has raised the Price Target to $ 84 from a previous price target of $70 .St. Jude Medical was Downgraded by Leerink Partners to ” Mkt Perform” on Jul 11, 2016. St. Jude Medical was Downgraded by Sun Trust Rbsn Humphrey to ” Neutral” on May 10, 2016.

St. Jude Medical Inc. develops manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management cardiovascular and atrial fibrillation therapy areas and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. Its six principal product categories include tachycardia implantable cardioverter defibrillator (ICD) systems bradycardia pacemaker systems atrial fibrillation (AF) products (electrophysiology introducers and catheters advanced cardiac mapping navigation and recording systems and ablation systems) vascular products (vascular closure products pressure measurement guidewires optical coherence tomography (OCT) imaging products heart failure monitoring device and other vascular accessories) structural heart products and neuromodulation products (spinal cord stimulation and radiofrequency ablation to treat chronic pain and deep brain stimulation to treat movement disorders).

Leave a Reply

St. Jude Medical - Is it time to Sell?

Top Brokerage Firms are advising their investors on St. Jude Medical. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.